|
Name |
Tricycloalternarene 2a
|
| Molecular Formula | C21H30O4 | |
| IUPAC Name* |
5-hydroxy-1-[(E)-7-hydroxy-6-methylhept-5-en-2-yl]-3a-methyl-3,5,6,7,9,9a-hexahydrocyclopenta[b]chromen-8-one
|
|
| SMILES |
CC(CC/C=C(\C)/CO)C1=CCC2(C1CC3=C(O2)C(CCC3=O)O)C
|
|
| InChI |
InChI=1S/C21H30O4/c1-13(12-22)5-4-6-14(2)15-9-10-21(3)17(15)11-16-18(23)7-8-19(24)20(16)25-21/h5,9,14,17,19,22,24H,4,6-8,10-12H2,1-3H3/b13-5+
|
|
| InChIKey |
BDMIMSPBTFWTBC-WLRTZDKTSA-N
|
|
| Synonyms |
Tricycloalternarene 2a; 103873-60-5; 3,3a,6,7,9,9a-hexahydro-5-hydroxy-1[(e)-7-hydroxy-6-methylhept-5-en-2-yl]-3a-methylcyclopenta[b]chromen-8(5h)-one; Cyclopenta(b)(1)benzopyran-8(3H)-one, 3a,5,6,7,9,9a-hexahydro-5-hydroxy-1-(6-hydroxy-1,5-dimethyl-4-hexenyl)-3a-methyl-
|
|
| CAS | 103873-60-5 | |
| PubChem CID | 6443494 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 346.5 | ALogp: | 2.1 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 66.8 | Aromatic Rings: | 3 |
| Heavy Atoms: | 25 | QED Weighted: | 0.733 |
| Caco-2 Permeability: | -4.508 | MDCK Permeability: | 0.00002150 |
| Pgp-inhibitor: | 0.023 | Pgp-substrate: | 0.005 |
| Human Intestinal Absorption (HIA): | 0.149 | 20% Bioavailability (F20%): | 0.907 |
| 30% Bioavailability (F30%): | 0.023 |
| Blood-Brain-Barrier Penetration (BBB): | 0.785 | Plasma Protein Binding (PPB): | 78.92% |
| Volume Distribution (VD): | 1.333 | Fu: | 10.99% |
| CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.195 |
| CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.581 |
| CYP2C9-inhibitor: | 0.023 | CYP2C9-substrate: | 0.221 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.594 |
| CYP3A4-inhibitor: | 0.435 | CYP3A4-substrate: | 0.261 |
| Clearance (CL): | 15.152 | Half-life (T1/2): | 0.637 |
| hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.323 |
| Drug-inuced Liver Injury (DILI): | 0.317 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.576 | Maximum Recommended Daily Dose: | 0.527 |
| Skin Sensitization: | 0.042 | Carcinogencity: | 0.882 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.026 |
| Respiratory Toxicity: | 0.714 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001868 | ![]() |
0.792 | D0T2PL | ![]() |
0.238 | ||
| ENC005805 | ![]() |
0.792 | D04VIS | ![]() |
0.234 | ||
| ENC005807 | ![]() |
0.792 | D02VPX | ![]() |
0.231 | ||
| ENC003211 | ![]() |
0.704 | D08SVH | ![]() |
0.228 | ||
| ENC003123 | ![]() |
0.655 | D0K5WS | ![]() |
0.225 | ||
| ENC005806 | ![]() |
0.628 | D0L7AS | ![]() |
0.222 | ||
| ENC004443 | ![]() |
0.624 | D04ATM | ![]() |
0.221 | ||
| ENC003212 | ![]() |
0.551 | D0Y7IU | ![]() |
0.220 | ||
| ENC003124 | ![]() |
0.511 | D04QNO | ![]() |
0.220 | ||
| ENC003577 | ![]() |
0.505 | D05BTM | ![]() |
0.218 | ||